ClinicalTrials.gg

Program

cyclobenzaprine

Also written as “TNX-102 SL”, “TNX-102 SL 5.6 mg” and “Treatment A”.

Its studies are mostly in Fibromyalgia · Stress Disorders, Post-Traumatic · Depressive Disorder, Major · Post-Acute COVID-19 Syndrome · Neck Pain, led by 7 companies.

Furthest: phase 4, since Jul 12, 201332 company-led studies, 2 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tonix Pharmaceuticals262 open or runningphase 3since Jul 12, 2013Dec 7, 2011Feb 2028phase 2 · NCT07621237
Eurofarma Laboratorios10 open or runningphase 3since Apr 24, 2012Apr 24, 2012none ahead
Johnson & Johnson10 open or runningphase 4since Oct 28, 2005Oct 28, 2005none ahead
Neurana Pharmaceuticals10 open or runningphase 1since Nov 14, 2017Nov 14, 2017none ahead
Novartis10 open or runningphase 1since Jun 2, 2009Jun 2, 2009none ahead
Sun Pharmaceutical Industries10 open or runningno phasesince Oct 22, 2008Oct 22, 2008none ahead
Takeda10 open or runningphase 3since Jun 23, 2016Jun 23, 2016none ahead

Also a collaborator on its studies: altasciences-company-inc, premier-research-group-plc and cognitive-research-corporation.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Oct 28, 2005.

  1. Apr 25, 2017Phase 1 study in Healthy AdultsTonix Pharmaceuticals · NCT03168022 · 43 enrolled · Canada
  2. Nov 14, 2017Neurana Pharmaceuticals's first study: phase 1 study in Driving ImpairedNew to Neurana PharmaceuticalsNeurana Pharmaceuticals · NCT03353922 · 35 enrolled · United States
  3. Feb 6, 2018Phase 1 study in Healthy SubjectsTonix Pharmaceuticals · NCT03443960 · 60 enrolled · Canada
  4. Apr 12, 2018Phase 3 study in Stress Disorders, Post-TraumaticTonix Pharmaceuticals · NCT03508700 · 93 enrolled · United States
  5. Feb 12, 2019Phase 3 study in Stress Disorders, Post-TraumaticTonix Pharmaceuticals · NCT03841773 · 192 enrolled · United States
  6. Nov 13, 2019Phase 1 study in Healthy SubjectsTonix Pharmaceuticals · NCT04164719 · 16 enrolled · Canada
  7. Nov 20, 2019Phase 3 study in FibromyalgiaTonix Pharmaceuticals · NCT04172831 · 503 enrolled · United States
  8. Aug 7, 2020Phase 3 study in FibromyalgiaTonix Pharmaceuticals · NCT04508621 · 514 enrolled · United States
  9. Mar 1, 2022Phase 3 study in FibromyalgiaTonix Pharmaceuticals · NCT05273749 · 457 enrolled · United States
  10. May 9, 2022Phase 2 study in Stress Disorders, Post-TraumaticTonix Pharmaceuticals · NCT05372887 · Kenya
  11. Jul 21, 2022Phase 2 study in InfectionsTonix Pharmaceuticals · NCT05472090 · 63 enrolled · United States
  12. Jan 26, 2026Phase 1 study in PharmakokineticTonix Pharmaceuticals · NCT07413367 · 50 enrolled · Canada
  13. Mar 6, 2026Phase 1 study in Healthy Subjects (HS)Tonix Pharmaceuticals · NCT07464535 · 20 enrolled · United States
  14. May 27, 2026Phase 2 study in Depressive Disorder, MajorTonix Pharmaceuticals · NCT07621237 · 360 planned · United States

Ahead

  1. Feb 2028Primary completion: phase 2 study in Depressive Disorder, MajorTonix Pharmaceuticals · NCT07621237

TargetBeta

HTR2A →HTR2C →read by rule
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
RisperidoneruleJohnson & Johnsonphase 4111
OlanzapineruleEli Lillyphase 476
TrazodoneruleAngelini Pharmaphase 314

Studies

All 32 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07621237Depressive Disorder, Major · United States2RecruitingTonix PharmaceuticalsFeb 2028360
NCT07464535Healthy Subjects (HS) · United States1CompletedTonix PharmaceuticalsApr 30, 202220
NCT07413367Pharmakokinetic · Canada1Active, not recruitingTonix PharmaceuticalsFeb 10, 202650
NCT05472090Infections · United States2CompletedTonix PharmaceuticalsJul 12, 202363
NCT05372887Stress Disorders, Post-Traumatic · Kenya2WithdrawnTonix PharmaceuticalsNov 8, 20220
NCT05273749Fibromyalgia · United States3CompletedTonix PharmaceuticalsNov 14, 2023457
NCT04508621Fibromyalgia · United States3CompletedTonix PharmaceuticalsNov 1, 2021514
NCT04172831Fibromyalgia · United States3CompletedTonix PharmaceuticalsOct 29, 2020503
NCT04164719Healthy Subjects · Canada1CompletedTonix PharmaceuticalsDec 24, 201916
NCT03841773Stress Disorders, Post-Traumatic · United States3TerminatedTonix PharmaceuticalsApr 24, 2020192
NCT03508700Stress Disorders, Post-Traumatic · United States3CompletedTonix PharmaceuticalsSep 30, 201993
NCT03443960Healthy Subjects · Canada1CompletedTonix PharmaceuticalsApr 9, 201860
NCT03353922Driving Impaired · United States1CompletedNeurana PharmaceuticalsDec 6, 201735
NCT03168022Healthy Adults · Canada1CompletedTonix PharmaceuticalsJan 26, 201643
NCT03110575Stress Disorders, Post-Traumatic · United States3TerminatedTonix PharmaceuticalsJul 27, 2018190
NCT03062540Stress Disorders, Post-Traumatic · United States3TerminatedTonix PharmaceuticalsJul 27, 2018358
NCT02829814Fibromyalgia · United States3TerminatedTonix PharmaceuticalsSep 13, 201651
NCT02814565Neck Pain · Russian Federation3CompletedTakedaFeb 10, 2017180
NCT02589275Fibromyalgia · United States3CompletedTonix PharmaceuticalsSep 28, 2016375
NCT02436096Fibromyalgia · United States3CompletedTonix PharmaceuticalsSep 2016519
NCT02421679Stress Disorders, Post-Traumatic · United States2CompletedTonix PharmaceuticalsMay 26, 2016159
NCT02277704Stress Disorders, Post-Traumatic · United States2CompletedTonix PharmaceuticalsMay 2016245
NCT02015234Fibromyalgia · United States3CompletedTonix PharmaceuticalsAug 2015158
NCT01903265Fibromyalgia · United States3CompletedTonix PharmaceuticalsJul 2014205
NCT01889173Healthy Adults · Canada1CompletedTonix PharmaceuticalsDec 201324
NCT01689259Healthy Adults · Canada1CompletedTonix PharmaceuticalsDec 201324
NCT01634412Healthy Adults · Canada1CompletedTonix PharmaceuticalsSep 201324
NCT01587508Acute Lumbago · Brazil3WithdrawnEurofarma LaboratoriosMay 20130
NCT01490788Healthy · Canada1CompletedTonix PharmaceuticalsDec 30, 201130
NCT00913419Depression1CompletedNovartisDec 198830
NCT00778037Healthy · India–CompletedSun Pharmaceutical IndustriesSep 200640
NCT00246389Pain4CompletedJohnson & Johnson1,000

How it is read

Names in the registry

  • “TNX-102 SL”, 13 entries
  • “TNX-102 SL 5.6 mg”, 2 entries
  • “Treatment A”, 2 entries
  • “Treatment B”, 2 entries
  • “TNX-102 SL Tablet”, 1 entry

Codes read as this program: TNX102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.